Autologous Vax-NK/HCC Consolidation Therapy in Patients with Extensive Stage Small Cell Lung Cancer
- Conditions
- Neoplasms
- Registration Number
- KCT0008301
- Lead Sponsor
- Chonnam National University Hospital Hwasun Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 12
1) Patients who are histologically or cytologically confirmed to have extensive stage small cell lung cancer.
2) Patients with no tumor progression observed after 4 cycles of the first-line chemoimmunotherapy (ACE regimen)
3) an adult over the age of 19
4) Patients with ECOG performance score below 2
5) Patients who have signed and agreed to participate in this clinical study
6) A patient who has obtained a consent form for donation to the Biobank of Chonnam National University Hwasun Hospital
7) Patients who meet the following conditions in a blood test.
- Absolute neutrophil count (ANC) = 1.0 x 10^9/L
- White blood cells count (WBC) = 3.0 x 10^9/L
- Serum bilirubin = 2.5 x Normal range
- AST and ALT = 2.5 × Normal Range
1) Patients who are not histologically or cytologically small cell lung cancer
2) Patients observed progression of disease after 2 cycles of first-line chemoimmunotherapy (ACE regimen)
3) Patients who have not completed primary ACE regimen up to 4 cycles
4) Untreated active brain or central nervous system metastasis
5) Uncontrolled cardiovascular disease (e.g., myocardial infarction and unstable angina within 3 months)
6) an uncontrolled, active infectious disease
7) a patient with autoimmune disease
8) Pregnant women, lactating women, or pregnant women who do not use proper contraception.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival
- Secondary Outcome Measures
Name Time Method Overall survival